| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 26, 2026 | CHMP recommends revoking marketing authorisation for TAVNEOS® (avacopan) in the European Union | Recommendation follows an Article 20 non-pharmacovigilance procedure
Patients currently on TAVNEOS treatment should consult their treating physician
ST. GALLEN, Switzerland, June 26, 2026 /PRNewswire/ -- Vifor Fresenius Medical Care Renal P... |
| Oct 27, 2025 | CSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE) | Setting new standards in responsible innovation, CSL's Broadmeadows facility blends Pharma 4.0™ principles with sustainable design to transform plasma manufacturing
BROADMEADOWS, AUSTRALIA, Oct. 27, 2025 /PRNewswire/ -- CSL's base... |
| Jun 24, 2025 | Australian firms face surge in AI cyber threats amid skill gaps | |
| Jun 24, 2025 | Most firms in ANZ slow to hire AI leaders as security worries grow | |
| Mar 25, 2025 | Australian enterprises gear up for AI agent integration push | |
| Feb 12, 2025 | Australian firms face data hurdles in AI deployment, study finds | |
| Feb 4, 2025 | Australian businesses urged to join data security framework | |
| Nov 6, 2024 | Joanne Gorton backed by Deloitte board to become next CEO | Joanne Gorton has firmed as the next chief executive of Deloitte in Australia, selected by the board as its preferred candidate to replace Adam Powick.
Deloitte partners will have the opportunity to vote on the recommendation towards the en... |
| Feb 13, 2024 | Half year reported NPATA US$2 billion¹,² Up 13% at constant currency³ | Strong CSL Behring portfolio growth especially Ig
FINANCIAL HIGHLIGHTS4
Revenue $8.05 billion, up 11% at CC3
NPAT $1.90 billion1, up 17%
NPAT $1.94 billion1 at CC3, up 20%
NPATA $2.02 billion1,2 , up 11%
NPATA $2.06 billion1,2 at CC3, up 13... |
| Oct 12, 2023 | CSL Signs Renewable-Linked Power Purchase Agreement with AGL to Supply Electricity to Australian Manufacturing Sites | MELBOURNE, Australia, Oct. 12, 2023 /PRNewswire/ -- Global biotechnology leader CSL (ASX: CSL; USOTC: CSLLY) announced today that it has signed a Renewable-Linked Power Purchase Agreement (PPA) with Australian energy provider, AGL. AGL was ... |
| Feb 26, 2023 | CSL's Phase 3 Study Shows First-In-Class Garadacimab Provides Patients with Significant HAE Attack Prevention with Monthly Dosing | Majority of patients were attack free during the entire six-month treatment period (61.5%) Study results presented for first time at 2023 AAAAI Annual Meeting; global regulatory submissions anticipated later in the calendar year Garadacimab... |
| Dec 13, 2022 | CSL Announces Next CEO & Managing Director | Dr Paul McKenzie appointed Chief Executive Officer and Managing Director of CSL from 6 March 2023
MELBOURNE, Australia, Dec. 13, 2022 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has a... |
| Dec 14, 2021 | CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd | MELBOURNE, Australia and ST. GALLEN, Switzerland, Dec. 14, 2021 /PRNewswire/ --
CSL Limited Announces Tender Offer To Acquire Vifor Pharma Ltd
- Agreement Announced on the Australian Stock Exchange and SIX Swiss Exchange 14 December, 2021
-... |
| Dec 13, 2016 | Brandon Capital to lead Biomedical Translation Fund Consortium in government initiative to make Australia a global leader in life science research commercialisation | Medical Research Commercialisation Fund (MRCF) creates fourth and largest fund as part of new initiative |
| Oct 10, 2013 | CSL settles plasma price-fixing case for $64M | CSL Ltd. (ASX:CSL) said it agreed to pay $64 million to settle multi-district litigation accusing it of taking part in a price-fixing scheme for plasma therapy.
The settlement also clears a co-defendant in the case, the Plasma Protein Thera... |
| Sep 7, 2012 | The world’s top five most innovative businesses | What defines innovation? Is it the creation of new ideas or the commercialisation of them?
Is it something that comes from a lone entrepreneur working tirelessly on a ground-breaking project or is it something that can be embedded within a ... |
| Jun 1, 2011 | Grifols and Talecris get FTC approval to merge | The FTC had been concerned that a merger of two of the top companies in the specialized blood therapeutics space would hurt competition and lead to higher drug costs for patients. The FTC raised antitrust concerns in 2009 when it blocked a ... |
| Apr 11, 2011 | Talecris-Grifols merger: investors showing growing confidence in the deal | The Talecris Biotherapeutics acquisition by Spanish company Grifols (MCE:GRF) looks like it’s moving closer to receiving regulatory approval, at least that’s how stock traders view the deal.
Bloomberg Businessweek reports that investors hav... |
| Feb 13, 2011 | Can blood therapy bear one less firm? Talecris, Grifols on brink of merger | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Sep 16, 2009 | FDA approves four H1N1 flu vaccines, no shortage expected – MedCity Morning Read, Sept. 16, 2009 | Promoted
Covid-19’s terrible toll on diabetes patients. What can be done?
The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Talecris-Grifols merger: investors showing growing confidence in the deal | The Talecris Biotherapeutics acquisition by Spanish company Grifols (MCE:GRF) looks like it’s moving closer to receiving regulatory approval, at least that’s how stock traders view the deal.
Bloomberg Businessweek reports that investors hav... |
| Can blood therapy bear one less firm? Talecris, Grifols on brink of merger | On a day when lovers and spouses profess their love, Talecris Biotherapeutics shareholders will vote whether to bless the $3.4 billion marriage of their company to Spanish suitor Grifols.
Talecris (NASDAQ:TLCR) shareholders are gathering ne... |
| FDA approves four H1N1 flu vaccines, no shortage expected – MedCity Morning Read, Sept. 16, 2009 | Image via Wikipedia
WASHINGTON, D.C. – The U.S. Food and Drug Administration has approved four vaccines to guard against the H1N1 flu virus – and there will be enough doses to go around, Reuters reported Tuesday.
Health and Human Servi... |
| Grifols and Talecris get FTC approval to merge | Grifols‘ (MCE:GRF) $4 billion acquisition of Talecris Biotherapeutics (NASDAQ:TLCR) now has the regulatory clearance to close.
Barcelona, Spain-based Grifols said Wednesday that the U.S. Federal Trade Commission has accepted a consent agree... |